Patents by Inventor Stuart W. Young
Stuart W. Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040023891Abstract: Compounds, pharmaceutical formulations and methods for use in neutron capture therapy are provided, useful for treating diseases characterized by neoplastic tissue and arteriosclerosis.Type: ApplicationFiled: February 25, 2003Publication date: February 5, 2004Inventors: Tarak D Mody, Jonathan L Sessler, Stuart W Young
-
Publication number: 20020115649Abstract: The present invention provides methods for treating disease of a subject in need thereof by sensitizing the effects of a co-therapeutic agent in macrophages. The method comprises administering a texaphyrin and a co-therapeutic agent to the subject. Texaphyrins are provided for enhancing the cytotoxicity of therapeutic agents in macrophage-mediated disease since texaphyrins have been shown to accumulate in macrophage.Type: ApplicationFiled: January 5, 2001Publication date: August 22, 2002Applicant: Pharmacyclics, Inc.Inventors: Kathryn W. Woodburn, Stuart W. Young
-
Patent number: 6375930Abstract: Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen.Type: GrantFiled: November 20, 1997Date of Patent: April 23, 2002Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.Inventors: Stuart W. Young, Meredith Wright, Jonathan L. Sessler, Tarak D. Mody, Darren Magda
-
Publication number: 20020025298Abstract: The use of texaphyrins for ocular diagnosis and therapy is provided, especially use of photosensitive texaphyrins for photodynamic therapy of conditions of the eye characterized by abnormal vasculature, such as macular degeneration, or pterygium, for example. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the photosensitive texaphyrin is metallated with lutetium. Due to the dual wavelength absorption of texaphyrins, i.e., at 400-500 nm and at 700-800 nm, especially about 732 nm, as compared to porphyrins, texaphyrins are more effective and versatile for use in humans as compared to porphyrins. Texaphyrins serve as effective contrast agents in ocular angiography.Type: ApplicationFiled: August 2, 2001Publication date: February 28, 2002Applicant: Pharmacyclics, Inc.Inventors: Mark S. Blumenkranz, Kathryn W. Woodburn, Richard A. Miller, Stuart W. Young
-
Publication number: 20020006378Abstract: Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen.Type: ApplicationFiled: November 20, 1997Publication date: January 17, 2002Inventors: STUART W. YOUNG, MEREDITH WRIGHT, JONATHAN L. SESSLER, TARAK D. MODY, DARREN MAGDA
-
Patent number: 6270749Abstract: The use of texaphyrins for ocular diagnosis and therapy is provided, especially use of photosensitive texaphyrins for photodynamic therapy of conditions of the eye characterized by abnormal vasculature, such as macular degeneration, or pterygium, for example. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the photosensitive texaphyrin is metallated with lutetium. Due to the dual wavelength absorption of texaphyrins, i.e., at 400-500 nm and at 700-800 nm, especially about 732 nm, as compared to porphyrins, texaphyrins are more effective and versatile for use in humans as compared to porphyrins. Texaphyrins serve as effective contrast agents in ocular angiography.Type: GrantFiled: June 10, 1999Date of Patent: August 7, 2001Assignee: Pharmacyclics, Inc.Inventors: Mark S. Blumenkranz, Kathryn W. Woodburn, Richard A. Miller, Stuart W. Young
-
Patent number: 6022526Abstract: Melanotic melanoma tumor or cells, melanin, or melanin metabolites are detected, identified, and localized when bound to texaphyrins or texaphyrin metal complexes. The present invention provides texaphyrins and texaphyrin metal complexes as reagents for in vivo or in vitro detection for melanin or melanin metabolites predictive of the presence of melanotic melanoma.Type: GrantFiled: July 30, 1997Date of Patent: February 8, 2000Assignee: Pharmacyclics, Inc.Inventors: Kathryn W. Woodburn, Stuart W. Young
-
Patent number: 5817017Abstract: Catheters and other medical devices include a non-metallic member having paramagnetic ionic particles fixedly incorporated therethrough in order to provide enhanced detectability when viewed by magnetic imaging regardless of the orientation of the non-metallic member in the magnetic field. Catheters are usually formed from polymeric tubing, and the paramagnetic ionic particles are usually formed from paramagnetic ions incorporated with water or other proton-donating fluid into carrier particles, such as zeolites, molecular sieves, clays, synthetic ion exchange resins, and microcapsules. Catheters and other medical devices include a non-metallic member having small iron and/or superparamagnetic particles fixedly incorporated therethrough or thereover in order to provide enhanced detectability when viewed by magnetic imaging.Type: GrantFiled: May 24, 1995Date of Patent: October 6, 1998Assignee: Pharmacyclics, Inc.Inventors: Stuart W. Young, Richard A. Miller
-
Patent number: 5775339Abstract: The present invention involves the use of a photosensitive texaphyrin for the photodynamic treatment of a pigmented lesion, such as a melanodermic lesion, or a lesion obscured by pigmented tissue such as melaniferous tissue in a subject. In particular, the invention provides a treatment for the metastatic process of melanoma, and a method for inhibiting growth of established metastases of melanoma. The photosensitive texaphyrin may be a free-base texaphyrin or may be metallated with a diamagnetic metal. Preferably, the texaphyrin is metallated with lutetium. Heretofore, melanoma has been refractory to treatment with photodynamic therapy.Type: GrantFiled: August 19, 1997Date of Patent: July 7, 1998Assignee: Pharmacyclics, Inc.Inventors: Kathryn W. Woodburn, Qing Fan, Stuart W. Young
-
Patent number: 5776925Abstract: Methods for cancer chemosensitization are provided. Texaphyrins are new chemosensitizers for enhancing the cytotoxicity of chemotherapeutic agents. The enhancement appears to be P-glycoprotein-independent since texaphyrins are effective in both a P-glycoprotein-expressing and a P-glycoprotein -nonexpressing cell line. Methods are provided for the treatment of cancers such as leukemia, lymphoma, carcinoma, and sarcoma using a texaphyrin as a chemosensitizer.Type: GrantFiled: January 25, 1996Date of Patent: July 7, 1998Assignee: Pharmacyclics, Inc.Inventors: Stuart W. Young, Richard A. Miller
-
Patent number: 5429814Abstract: The invention relates to a method of using molecular sieve-enclosed paramagnetic ions as image brightening or image contrast agents. In particular, zeolite enclosed trivalent gadolinium is useful in MRI studies of the entire gastrointestinal tract, providing excellent images. Zeolite-enclosed gadolinium complexes may be conveniently administered in oral preparations without side effects of diarrhea. Other transition metal ions, including divalent manganese may be enclosed in any suitable molecular sieve which has ion exchange properties sufficient to exchange the selected metal. The exchanged paramagnetic metal ion may be a free ion within the zeolite framework or ligated with a chelator. Alternatively, a paramagnetic metal ion may be included as part of the molecular sieve framework.Type: GrantFiled: May 27, 1993Date of Patent: July 4, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Stuart W. Young, Kenneth J. Balkus, Jr., A. Dean Sherry
-
Patent number: 5122363Abstract: The invention relates to a method of using zeolite enclosed paramagnetic ions as image brightening or image contrast agents. In particular, zeolite enclosed trivalent gadolinium is useful in MRI studies of the entire gastrointestinal tract, providing excellent images. Zeolite-enclosed gadolinium complexes may be conveniently administered in oral preparations without side effects of diarrhea. Other transition metal ions, including divalent manganese may be enclosed in any suitable zeolite which has ion exchange properties sufficient to exchange the selected metal.Type: GrantFiled: December 7, 1990Date of Patent: June 16, 1992Assignee: Board of Regents, The University of Texas SystemInventors: Kenneth J. Balkus, Jr., A. Dean Sherry, Stuart W. Young